[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Haematology](https://durgical.com/en/haematology/) › [Myeloid neoplasms](https://durgical.com/en/haematology/areas/myeloid/) › Stem cell transplantation: autologous or allogeneic, and what can go wrong

# Stem cell transplantation: autologous or allogeneic, and what can go wrong

- Treatment and support

A stem cell transplant replaces a damaged or cancerous marrow. Knowing whose cells are given predicts the risks, from infections to [graft-versus-host disease](https://durgical.com/en/conditions/graft-versus-host-disease/).

Updated Nov 15, 2026

## Key points

- Auto = rescue after high-dose chemotherapy (myeloma, lymphoma); allo = new immune system ([acute leukaemia](https://durgical.com/en/conditions/acute-leukaemia/), MDS, aplasia).
- Allo brings graft-versus-leukaemia and GvHD; auto brings neither.
- Acute GvHD: skin, [liver](https://durgical.com/en/anatomy/liver/), gut; chronic GvHD looks like autoimmune disease.
- Infections by phase: bacteria and fungi in aplasia, CMV in the first months, encapsulated bacteria later.
- After transplant: irradiated products, CMV monitoring, revaccination.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- How it is done (and why)
- Autologous versus allogeneic
- Common traps
- Elsewhere in DurgiPedia

- Safety Risks and precautions
- Monitoring and next step

- Study Test yourself

- Connections Connections

## What it is

Haematopoietic stem cell transplantation gives blood-forming stem cells after conditioning treatment. In an autologous transplant the patient's own cells, collected beforehand, rescue the marrow after very intensive chemotherapy. In an allogeneic transplant cells come from a donor (a matched sibling, a matched unrelated donor, a half-matched relative or cord blood) and bring a new immune system that can attack residual cancer (graft-versus-leukaemia) but also the patient's tissues (graft-versus-host disease, GvHD). Cells are collected from blood after mobilisation, from the marrow, or from umbilical cord blood.

## How to think about it

An autologous transplant is a rescue: the cure is the high-dose chemotherapy, and the stored cells are the seeds saved before scorching the field. An allogeneic transplant is a new immune system: the donor's cells are themselves part of the treatment, policing the cancer for years, but they may also turn on the host. Auto risks are about the scorched field; allo risks are about the new police force.

## What to know

- Typical autologous uses: [multiple myeloma](https://durgical.com/en/conditions/multiple-myeloma/) and relapsed lymphoma (and some others); no GvHD and no graft-versus-leukaemia effect.
- Typical allogeneic uses: high-risk or relapsed acute leukaemias, MDS, myelofibrosis, CML that fails TKIs, severe [aplastic anaemia](https://durgical.com/en/conditions/aplastic-anaemia/), and inherited diseases such as [sickle cell disease](https://durgical.com/en/conditions/sickle-cell-disease/) and [thalassaemia](https://durgical.com/en/conditions/thalassemias/) major.
- Donor [matching](https://durgical.com/en/epidemiology/matching/) relies on HLA; a sibling has a one-in-four chance of being fully matched, and half-matched (haploidentical) family donors have widened access.
- Conditioning is myeloablative (kills the marrow) or reduced-intensity (relies more on the donor immune system, gentler for older or frailer patients).
- Engraftment is the recovery of neutrophils from the new cells, usually 2 to 4 weeks after infusion; platelets recover later.
- Acute GvHD hits the skin (rash, often palms and soles), liver (cholestatic jaundice) and gut (diarrhoea); chronic GvHD resembles autoimmune disease ([dry eyes](https://durgical.com/en/conditions/dry-eye-disease/) and mouth, skin tightening, lung scarring).

## How it is done (and why)

- Collect: mobilise stem cells into the blood with growth factor and collect by apheresis (or harvest marrow, or use cord blood); store autologous cells frozen.
- Condition: chemotherapy, with or without [radiotherapy](https://durgical.com/en/nursing/radiation-therapy-skin-care-fatigue-and-safety-with-implants-and-radioactive-sou/), kills the disease, makes space and, in allogeneic transplants, stops the host rejecting the graft.
- Infuse the cells through a central line, like a transfusion; they find their way to the marrow.
- Support through aplasia: [neutropenic precautions](https://durgical.com/en/nursing/the-child-with-cancer-neutropenic-precautions-mucositis-nausea-the-central-line/), antimicrobial prophylaxis, irradiated blood products, nutrition and care of mucositis.
- Engraft: neutrophils return; in allogeneic transplants continue immunosuppression to prevent GvHD.
- Follow for months to years: CMV and other infection surveillance, GvHD, chimerism, revaccination and late effects.

## Autologous versus allogeneic

| Feature | Autologous | Allogeneic |
| --- | --- | --- |
| Source of cells | Patient's own, collected before | Donor: sibling, unrelated, half-matched relative, cord blood |
| What cures the disease | The high-dose chemotherapy | Conditioning plus the donor immune system (graft-versus-leukaemia) |
| GvHD | No | Yes, acute and chronic |
| Rejection | No | Possible ([graft failure](https://durgical.com/en/conditions/skin-grafts-and-flaps-covering-a-wound/)) |
| Infection risk | Mainly during the weeks of aplasia | Higher and longer: immunosuppression, GvHD, viruses such as CMV |
| Treatment-related mortality | Low | Higher; varies with age, donor and conditioning |

## Risks and precautions

- Infections follow a timeline: in the aplasia, bacteria, Candida, [Aspergillus](https://durgical.com/en/microbiology/aspergillus-fumigatus/) and herpes simplex; in the first months, CMV, [Pneumocystis](https://durgical.com/en/microbiology/pneumocystis-jirovecii/) and [adenovirus](https://durgical.com/en/microbiology/adenovirus/); later, encapsulated bacteria and [varicella](https://durgical.com/en/conditions/varicella/) - [zoster](https://durgical.com/en/conditions/herpes-zoster/), especially with chronic GvHD.
- Fever in the first weeks is [febrile neutropenia](https://durgical.com/en/conditions/febrile-neutropenia/) until proven otherwise: start empirical intravenous antibiotics within the hour.
- Painful enlarged liver, jaundice and weight gain from fluid in the first weeks suggest sinusoidal obstruction syndrome (veno-occlusive disease) after conditioning.
- All cellular blood products after transplant are irradiated, to prevent transfusion-associated GvHD; after an ABO-mismatched transplant the blood group changes to the donor's, so the blood bank must know.
- The immune memory is lost: patients are revaccinated from scratch, and live vaccines wait until immunity has recovered.

## Monitoring and next step

- Daily count during aplasia; engraftment is the first of several days with neutrophils above 0.5 × 10⁹/L.
- CMV PCR weekly in at-risk allogeneic recipients, with prophylaxis ([letermovir](https://durgical.com/en/pharmacology/letermovir/)) or pre-emptive treatment ([ganciclovir](https://durgical.com/en/pharmacology/ganciclovir/) or [valganciclovir](https://durgical.com/en/pharmacology/valganciclovir/), which suppress the marrow).
- Drug levels of [calcineurin inhibitors](https://durgical.com/en/pharmacology/classes/calcineurin-inhibitors/) ([ciclosporin](https://durgical.com/en/pharmacology/ciclosporin/), [tacrolimus](https://durgical.com/en/pharmacology/tacrolimus/)), plus kidney function, [magnesium](https://durgical.com/en/biochemistry/topics/magnesium/) and [blood pressure](https://durgical.com/en/physiology/systolic-diastolic-mean-and-pulse-pressure/).
- Chimerism (the share of donor cells in blood and marrow) and disease markers to detect graft failure or relapse.
- Suspected GvHD: skin, liver or gut biopsy when the diagnosis is uncertain; steroids are first line and [ruxolitinib](https://durgical.com/en/pharmacology/ruxolitinib/) for steroid-refractory disease.

## Common traps

- **Thinking an autologous transplant cures by the graft**: the cells only rescue the marrow; the cure is the chemotherapy.
- **Giving non-irradiated blood products to a transplant recipient**: transfusion-associated GvHD is almost always fatal.
- **Attributing diarrhoea after an allogeneic transplant to an infection only**: it may be gut GvHD (and vice versa: rule out CMV and [Clostridioides difficile](https://durgical.com/en/microbiology/clostridioides-difficile/)).
- **Giving a live vaccine too early after transplant**: live vaccines have to wait.
- **Assuming the blood group is the same as before an ABO-mismatched transplant**: after it the group is no longer the same.

## Test yourself

Think of the answer, then tap the question to see it.

## Why does a patient with acute myeloid leukaemia receive an allogeneic rather than an autologous transplant?

Because the donor immune system attacks remaining leukaemia cells (graft-versus-leukaemia), and the patient's own marrow may still carry the leukaemia.

## Which three organs does acute GvHD typically involve?

Skin (a rash, often on palms and soles), liver (cholestatic jaundice) and gut (diarrhoea, which can be profuse).

## Why are all cellular blood products irradiated for a transplant recipient?

Irradiation stops donor lymphocytes in the bag from multiplying and attacking a host that cannot reject them (transfusion-associated GvHD).

## Two months after an allogeneic transplant, which virus is watched for by weekly PCR, and why?

[Cytomegalovirus](https://durgical.com/en/microbiology/cytomegalovirus/): reactivation is common under immunosuppression and can cause pneumonitis, colitis and marrow suppression, so it is treated before disease appears.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/haematology/stem-cell-transplantation-autologous-or-allogeneic-and-what-can-go-wrong/)

## Elsewhere in DurgiPedia

- [Haematopoietic stem cell transplant: the immunology](https://durgical.com/en/immunology/haematopoietic-stem-cell-transplant-the-immunology/)
- [Graft-versus-host disease: the immunology](https://durgical.com/en/immunology/graft-versus-host-disease-the-immunology/)
- [HLA inheritance, typing and the crossmatch](https://durgical.com/en/immunology/hla-inheritance-typing-and-the-crossmatch/)
- [Leukaemia, lymphoma and stem-cell transplant: nursing care and graft-versus-host warning signs](https://durgical.com/en/nursing/leukaemia-lymphoma-and-stem-cell-transplant-nursing-care-and-graft-versus-host-w/)
- [The neutropenic and immunosuppressed patient (nursing)](https://durgical.com/en/immunology/the-neutropenic-and-immunosuppressed-patient/)

## Connections

## Related 7

- [Antibodies, bispecifics and CAR-T cells: how they work and their emergencies (CRS, ICANS)](https://durgical.com/en/haematology/antibodies-bispecifics-and-car-t-cells-how-they-work-and-their-emergencies/)
- [CML on tyrosine kinase inhibitors: response milestones and resistance](https://durgical.com/en/haematology/cml-on-tyrosine-kinase-inhibitors-response-milestones-and-resistance/)
- [Marrow failure: aplastic anaemia, PNH, hypoplastic MDS and inherited syndromes](https://durgical.com/en/haematology/marrow-failure-aplastic-anaemia-pnh-hypoplastic-mds-and-inherited-syndromes/)
- [Blood components: red cells, platelets, plasma and cryoprecipitate, and when each is used](https://durgical.com/en/haematology/blood-components-red-cells-platelets-plasma-and-cryoprecipitate-and-when-each-is/)
- [Acute leukaemias: AML, ALL and the emergency called APL](https://durgical.com/en/haematology/acute-leukaemias-aml-all-and-the-emergency-called-apl/)
- [Fever with low neutrophils: the first hour](https://durgical.com/en/haematology/fever-with-low-neutrophils-the-first-hour/)
- [Marrow aspirate and biopsy, flow cytometry and genetics: which test answers which question](https://durgical.com/en/haematology/marrow-aspirate-and-biopsy-flow-cytometry-and-genetics-which-test-answers-which/)

## Related conditions 6

- [Graft-versus-host disease](https://durgical.com/en/conditions/graft-versus-host-disease/)
- [Febrile neutropenia](https://durgical.com/en/conditions/febrile-neutropenia/)
- [Cytomegalovirus infection](https://durgical.com/en/conditions/cytomegalovirus-infection/)
- [Aspergillosis](https://durgical.com/en/conditions/aspergillosis/)
- [Acute leukaemia (AML and ALL)](https://durgical.com/en/conditions/acute-leukaemia/)
- [Multiple myeloma](https://durgical.com/en/conditions/multiple-myeloma/)

## In Pharmacology 10

- [Filgrastim](https://durgical.com/en/pharmacology/filgrastim/)
- [Busulfan](https://durgical.com/en/pharmacology/busulfan/)
- [Melphalan](https://durgical.com/en/pharmacology/melphalan/)
- [Cyclophosphamide](https://durgical.com/en/pharmacology/cyclophosphamide/)
- [Tacrolimus](https://durgical.com/en/pharmacology/tacrolimus/)
- [Methotrexate](https://durgical.com/en/pharmacology/methotrexate/)
- [Letermovir](https://durgical.com/en/pharmacology/letermovir/)
- [Ganciclovir](https://durgical.com/en/pharmacology/ganciclovir/)
- [Posaconazole](https://durgical.com/en/pharmacology/posaconazole/)
- [Ruxolitinib](https://durgical.com/en/pharmacology/ruxolitinib/)

[← All of haematology](https://durgical.com/en/haematology/)

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: [Stem Cell Transplants in Cancer Treatment](https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant) (National Cancer Institute, 2024); [Bone marrow transplant: MedlinePlus Medical Encyclopedia](https://medlineplus.gov/ency/article/003009.htm) (U.S. National Library of Medicine, 2026); [Graft-versus-host disease](https://medlineplus.gov/ency/article/001309.htm) (MedlinePlus, U.S. National Library of Medicine, 2026); [Bone marrow transplant - discharge: MedlinePlus Medical Encyclopedia](https://medlineplus.gov/ency/patientinstructions/000010.htm) (MedlinePlus, US National Library of Medicine, 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/haematology/stem-cell-transplantation-autologous-or-allogeneic-and-what-can-go-wrong/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/haematology/stem-cell-transplantation-autologous-or-allogeneic-and-what-can-go-wrong/
